A significant fraction of advanced PCa treated
with androgen deprivation therapy experience relentless progression to lethal metastatic castration - resistant prostate cancer (mCRPC).
Twenty - two patients with elevated prostate - specific antigen and biopsy - proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated
with androgen deprivation, radiation therapy, or both, and a Gleason - matched control group who had not received such therapy.
Not exact matches
«A significant number of advanced prostate cancer patients treated
with a chemical castration therapy called
androgen deprivation therapy (ADT) experience relapse
with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Biology.
The authors focused on men newly diagnosed
with localized (non-metastatic) prostate cancer in 1995 - 2011 and treated
with radical prostatectomy, brachytherapy, radiation therapy, or primary
androgen deprivation therapy (PADT).
Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumours when combined
with other techniques — in this case,
androgen deprivation therapy and external bean radiation therapy.»
All had been treated previously
with at least one type of
androgen deprivation therapy and had rising levels of prostate specific antigen (PSA), a blood marker for prostate cancer, and radiographic evidence their cancers were becoming resistant.
Preliminary results of a study of patients
with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to
androgen deprivation and radiation therapy, according to a team of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston.
Androgen deprivation therapy (ADT) is a common treatment option for patients
with advanced stage prostate cancer.
In current practice, men newly diagnosed
with prostate cancer that has spread widely, and whose cancer depends on male hormones to grow, are started on hormone - blocking medications —
androgen deprivation therapy (ADT).
Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to
androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients
with high - volume disease.
Treatment
with an investigational
androgen receptor inhibitor significantly delayed the development of metastasis in patients
with prostate cancer that had become resistant to standard
androgen -
deprivation therapy.
A second phase 3 study presented Sunday found that adding radiation to hormone therapy, also known as
androgen -
deprivation therapy (ADT) in patients
with locally advanced or high - risk prostate cancer reduced the seven - year risk of dying by 43 percent compared to treating
with hormone therapy alone.
With intermittent androgen deprivation, hormone therapy is given in cycles, with breaks between drug administrations, rather than continuou
With intermittent
androgen deprivation, hormone therapy is given in cycles,
with breaks between drug administrations, rather than continuou
with breaks between drug administrations, rather than continuously.